Clinical trial · Interventional
Radium-223 Dichloride Long-term Follow-up Program
A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride
NCT02312960CI-TRIAL-00087667completedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients will be followed up in this study after prior treatment with BAY88-8223 / Radium-223 dichloride / Xofigo.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm Metastasis / Bone and Bones | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data Collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Arm 1
- description
- The subjects previously enrolled in a selected radium-223 dichloride feeder trial, their treating health care professional, or caregiver will be contacted in 6-month intervals for follow up and query.
- interventionNames
- Other: Data Collection
Primary outcomes (12)
- measure
- Number of Participants With Radium-223 Dichloride-/Placebo-related Adverse Events (AEs)
- timeFrame
- Up to 7 years
- description
- Adverse events considered related to radium-223 dichloride or placebo (received in the feeder studies), first arising or worsening on or after the date the participant signed the 16996 informed consent.
- measure
- Severity of Radium-223 Dichloride-/Placebo-related Adverse Events (AEs)
- timeFrame
- Up to 7 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subject was previously enrolled in a selected company sponsored feeder trial, and has received at least 1 dose of radium 223 dichloride or placebo in the feeder trial Exclusion Criteria: * Not applicable to this follow up study
References
Publications (0)
Data not yet available
No reference posted for this study.